Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.